Vaccine manufacturer Serum Institute of India said on Sunday that "We are planning to start production of the Covid-19 vaccine developed by Oxford University in two to three weeks and by October if it is successful testing on humans The vaccine is expected to hit the market. Indeed, the Pune-based company Serum Institute of India is one of the seven global companies with which Oxford University has partnered to produce the vaccine. The Chief Executive Officer (CEO) of the company, Adar Poonawala said on Sunday that 'our team is working closely with Dr Hill of Oxford University. We hope to start production in the next two to three weeks. The first six months of production capacity will be 5 million doses per month. After this, we hope to increase production to one crore doses per month.
Relief from corona in Turkey, decreases in number of deaths
The Serum Institute of India has already worked with the University of Oxford on the malaria vaccine project, which you must have known about. Taking the matter further, Poonawalla said, "We expect the Covid-19 vaccine to hit the market by September-October, provided the vaccine test succeeds with the necessary safety and adequate efficacy." We will start testing this vaccine in India in the next two to three weeks. ”The company has also said that the process of taking necessary approvals to start testing this vaccine in India is underway.
Provision for death penalty for minors ended in Saudi, Shah Salmaan orders
Poonawala further emphasized his point and said, "Keeping in mind the current situation, we have financed this effort ourselves. We hope that we will get cooperation from other partners to increase production. The vaccines will be manufactured at the plant in Pune. If a separate plant is made to manufacture Covid-19 vaccines, then it will take about two to three years. ”With this, he said that the company will not patent this vaccine and it will be used by companies not only in India but around the world. Whoever develops the vaccine will need many partners to manufacture the vaccine.
